Mersana Therapeutics, Inc. Forms Scientific Advisory Board to Support Development of Next-Generation Antibody-Drug Conjugates
10/21/2013 6:45:48 AM
More...
|
Mersana Therapeutics, Inc. Earns Milestone Payment in Fleximer-ADC Collaboration With Endo Pharmaceuticals (ENDP)
10/15/2013 9:54:54 AM
More...
|
Adimab LLC. and Mersana Therapeutics, Inc. Announce Antibody-Drug Conjugate Alliance
8/1/2012 10:18:07 AM
More...
|
Mersana Therapeutics, Inc. Raises $27 Million to Advance Antibody-drug Conjugates
7/31/2012 8:12:12 AM
More...
|
Mersana Therapeutics, Inc. Strikes $270 Million Antibody-drug Conjugate Deal With Endo Pharmaceuticals (ENDP)
3/7/2012 7:45:31 AM
More...
|
With Cancer Drug in Trials, Mersana Therapeutics, Inc. Gets $6 Million
4/22/2011 7:09:53 AM
More...
|
Mersana Therapeutics, Inc. Appoints Michael A. Metzger as EVP & COO
4/20/2011 7:22:32 AM
More...
|
Mersana Therapeutics, Inc. Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
3/25/2011 7:11:34 AM
More...
|
Mersana Therapeutics, Inc. Appoints Nicholas Bacopoulos President and Chief Executive Officer
9/29/2010 6:46:15 AM
More...
|
Mersana Therapeutics, Inc. Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology
6/23/2010 9:25:29 AM
More...
|
|